WETO:NASDAQWetour Robotics Limited Analysis
Data as of 2026-05-10 - not real-time
$0.47
Latest Price
8/10Risk
Risk Level: High
Executive Summary
Wetour Robotics is trading well below its 20‑day (≈$0.52) and 50‑day (≈$0.51) simple moving averages, with the price hovering just above the identified support level of $0.45 and far under the 200‑day SMA of $1.12. Technical indicators such as a RSI of 45 and a bearish MACD histogram reinforce a neutral‑to‑downward bias, while the stock’s volatility of 124% (30‑day) and a beta of 1.42 signal extreme price swings relative to the market. Fundamentally, the company reports a massive revenue decline of 45%, operating margins of –115%, and a net loss reflected in a trailing EPS of –$0.15, compounded by a debt‑to‑equity ratio above 50 and a max drawdown of –90%, indicating severe financial distress. Liquidity is thin, with daily volume (~40k) well below its 3‑month average (~1.87M), and the market sentiment index shows “Extreme Greed,” likely driven by speculative short‑term interest rather than fundamentals. Recent headlines about a Rosen Law Firm‑led securities class‑action investigation add a layer of legal uncertainty, while the company’s rollout of the “Orchestra” platform and a college sponsorship event offer limited positive narrative but are insufficient to offset the prevailing downside risks.
Market Outlook
Short Term
< 1 yearCautious
Model confidence: 7/10
Key Factors
- Bearish MACD and price below short‑term SMAs
- Elevated volatility and beta increasing price swings
- Pending securities class‑action investigation
Medium Term
1–3 yearsNeutral
Model confidence: 5/10
Key Factors
- Introduction of the Orchestra platform could unlock future revenue
- Increasing trading volume suggests growing market interest
- Continued negative cash flow and high debt constrain upside
Long Term
> 3 yearsNeutral
Model confidence: 4/10
Key Factors
- Structural financial deficits and heavy leverage
- Uncertain path to profitability despite technology focus
- Potential for turnaround hinges on successful commercialization and financing
Key Metrics & Analysis
Financial Health
Revenue Growth-45.00%
Profit Margin-75.88%
ROE-60.52%
ROA-19.31%
Debt/Equity51.62
P/B Ratio1.3
Op. Cash Flow$-39541028
Free Cash Flow$-35448932
Industry P/E38.4
Technical Analysis
TrendNeutral
RSI45.0
Support$0.45
Resistance$0.63
MA 20$0.52
MA 50$0.51
MA 200$1.12
MACDBearish
VolumeIncreasing
Fear & Greed Index90.73
Valuation
GradeOvervalued
TypeValue
Risk Assessment
Beta1.42
Volatility124.22%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskHigh
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.